The optimal management of T1G3 bladder cancer.
Emiliozzi
Paolo
P
San Giovanni Hospital, Rome, Italy. paoloemiliozzi@hotmail.com
Pansadoro
Alberto
A
Pansadoro
Vito
V
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001500:BCG Vaccine / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D015653:Cystectomy / Q000379:methods*; D018450:Disease Progression; D005500:Follow-Up Studies; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D011379:Prognosis; D016019:Survival Analysis; D001749:Urinary Bladder Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*
D000970:Antineoplastic Agents; D001500:BCG Vaccine